간편하게 보는 뉴스는 유니콘뉴스
Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics

· 등록일 Jul. 11, 2024 11:41

· 업데이트일 2024-07-12 00:00:26

FRANKFURT, GERMANY--(Business Wire / Korea Newswire)--Merz Therapeutics announces today the successful acquisition of INBRIJA® (levodopa inhalation powder) and (F)AMPYRA® (fampridine), and related assets from Acorda Therapeutics, Inc. AMPYRA® (dalfampridine) is Food and Drug Administration (FDA) approved in the U.S. and commercialized as FAMPYRA in the European Union and other territories throughout the world. This transaction was conducted through a court-structured 363 sale under the U.S. Bankruptcy Code. The completion of this deal, valued at USD 185 million in cash, bolsters Merz Therapeutics’ market position by enhancing offerings for people living with Parkinson’s disease and expanding into the multiple sclerosis (MS) space.

“The addition of INBRIJA and (F)AMPYRA to the treatment portfolio underlines Merz Therapeutics’ global Pivot for Growth strategy to both evolve the current portfolio and achieve critical scale and global reach,” said Stefan König, CEO of Merz Therapeutics. “Merz Therapeutics is well poised to build on what we have accomplished in the specialty neurology space, strengthening our market position in Parkinson’s disease and expanding into the MS segment. This deal demonstrates Merz Therapeutics’ interest and ability to acquire assets that will deliver greater, sustainable outcomes for more people living with neurological disorders.”

INBRIJA and (F)AMPYRA are projected to immediately add topline revenue which will enhance Merz Therapeutics’ ability to accelerate clinical development of its existing and new assets. Its U.S. business is forecasted to contribute more than 75% of INBRIJA’s and (F)AMPYRA’s total global revenues over the next 10 years. Additionally, the company expects the U.S. workforce to increase by more than 50%.

INBRIJA is a significant advancement for people living with Parkinson’s disease as it provides an on-demand, inhalable form of levodopa, offering an effective way to manage “OFF” episodes. This method of delivery, achievable through the innovative and proprietary technology platform, ARCUS®, is especially valuable for people who need rapid relief from their symptoms, which cannot be achieved reliably through oral intake.

(F)AMPYRA is the first medication approved for improving walking in patients with MS, demonstrated by an improved walking ability.

“Expanding the portfolio with INBRIJA, including plans for worldwide product roll-out, and (F)AMPYRA allows Merz Therapeutics the opportunity to leverage its experience in the specialty neurology space to serve even more patients living with neurological disorders and support the physicians who treat them,” said Stefan Albrecht, Chief Scientific and Medical Officer. “Because these treatments complement the company’s product portfolio and distribution system, we are well positioned to support patients who depend on these products seamlessly.”

About INBRIJA

INBRIJA® is an inhaled prescription levodopa medicine used to treat the return of Parkinson’s symptoms (known as “OFF” episodes) in people with Parkinson’s disease who are treated with carbidopa/levodopa medicines. It does not replace the regular carbidopa/levodopa medicines. INBRIJA is not to be used by people with Parkinson’s disease who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine, within the last 2 weeks. The most common side effects of INBRIJA are cough, upper respiratory tract infection, nausea and change in the color of saliva or spit.

About FAMPYRA

FAMPYRA® is a prolonged-release (sustained release) tablet formulation of the drug fampridine (4-aminopyridine, 4-AP or dalfampridine). FAMPYRA is indicated in the European Union for the improvement of walking in adult patients with multiple sclerosis (MS) with walking disability (EDSS 4-7). In clinical trials, the highest incidence of adverse reactions identified with FAMPYRA given at the recommended dose was urinary tract infection. Other adverse drug reactions identified were mainly divided between neurological disorders such as insomnia, balance disorder, dizziness, paraesthesia and headache, and gastrointestinal disorders including nausea, dyspepsia and constipation. In post-marketing experience, there have been reports of seizure. Please see FAMPYRA EPAR for more information.

About AMPYRA

AMPYRA® is an extended-release tablet formulation of dalfampridine (4-aminopyridine, 4-AP or fampridine). AMPYRA is a potassium channel blocker approved as a treatment to help improve walking in adults with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. The most common side effects for AMPYRA in MS patients were urinary tract infection; trouble sleeping; dizziness; headache; nausea; weakness; back pain; problems with balance; multiple sclerosis relapse; burning, tingling, or itching of your skin; irritation in your nose and throat; constipation; indigestion; and pain in your throat. Please see the AMPYRA Patient Medication Guide for more information.

About Merz Therapeutics

Merz Therapeutics is dedicated to improving the lives of patients around the world. With its relentless research, development and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease and other health conditions that severely impact patients’ quality of life.

Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated 115 years to developing innovations that serve unmet patient and customer needs.

Please visit www.merztherapeutics.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240710459851/en/

Website: https://www.merz.com/ Contact Merz Therapeutics GmbH
Press Contact for Global Inquiries
Agnes Tesch
Global Communications
+49 69 1503 2129
[email protected]

Merz Therapeutics
Press Contact for North America Inquiries
Nicole Lovern
Corporate Communications
(571) 442-9665
[email protected]
This news is a press release provided by Merz Therapeutics. Korea Newswire follows these editorial guidelines. Merz Therapeutics News ReleasesSubscribeRSS Merz Enters Asset Purchase Agreement With a US-Based Biotech Company Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered into an Asset Purchase Agreement to acquire two commercial medicines from NASDAQ-listed Acorda Therapeutics. Closing of the transaction would significantly contribute to the accelerated growth strategy of Merz Ther... 4월 3일 15:20 멀츠, 미국 기반 생명공학 회사와 자산 매입 계약 체결 프랑크푸르트에 본사를 둔 멀츠 그룹(Merz Group)의 계열사인 멀츠 테라퓨틱스(Merz Therapeutics)가 나스닥 상장사 아코다 테라퓨틱스(Acorda Therapeutics)로부터 상업용 의약품 2종을 인수하는 자산 매입 계약을 체결했다. 이번 거래 체결은 메르츠 테라퓨틱스의 성장 전략 가속화에 크게 기여할 것이다. ... 4월 3일 15:20 ... More  More News Health Healthcare & Hospital Pharmaceutical Contract Overseas Merz Therapeutics All News Releases 
인기 기사12.23 15시 기준
서울--(뉴스와이어)--셀리드(코스닥 299660)는 코로나19 백신 AdCLD-CoV19-1 OMI에 적용된 독자적 아데노바이러스 벡터 플랫폼 기술에 대한 중국과 일본 특허 등록이 결정됐다고 9일 밝혔다. 이번 특허는 셀리드가 개발 중인 ‘AdCLD-CoV19-1 OMI’에 적용된 복제불능 아데노바이러스 대량생산에 최적화된 벡터 구조에...
SEOUL--(Korea Newswire)--The global ESG consulting firm, ECONINE, has received the highest rating, the Platinum medal, in the 2023 sustainability assessment from EcoVadis, the world’s most influential and trusted sustainability rating agency. ...
서울--(뉴스와이어)--용산청소년문화의집(관장 김종복)은 12월 6일 서울특별시청소년수련시설협회가 주관하는 ‘2023년 서울청소년지도자의 날’ 행사에서 우수청소년시설과 지도자의 전문성을 인정받아 ‘한국청소년수련시설협회장상(시설)’, ‘서울특별시의회 의장상(지도자)’ 2개 부문을 수상했다. 용산청소년문화의집, 2023 우수청소년시설·지도자상 2개부문 수상...
마닐라, 필리핀--(뉴스와이어)--프로캡 인터내셔널(Procap International)이 명동 로얄호텔서울에서 ‘프로캡 인터내셔널 - 자본 보호의 선두주자’ 세미나를 개최했다. 이 행사에는 150명이 넘는 전문가와 사업주, 기업가가 참석해 프로캡 인터내셔널의 영향력을 확인할 수 있었다. ...
서울--(뉴스와이어)--발달장애인의 직장 적응과 인권 보장을 위해 발달장애인의 특성을 잘 이해하고 있는 사회복지사가 발달장애인 바리스타 직무 분야 교육 지원에 나선다. ‘2023년 발달장애인 바리스타 강사 3기 양성과정’에...
버뮤다, 해밀턴--(Business Wire / 뉴스와이어)--가족 소유의 주류 회사인 바카디(Bacardi)가 이달 초 진행된 시범 운영에서 수소를 연료로 사용하는 유리 증류주 병의 세계 최초 상업적 생산을 성공적으로 완료했다. ...
API
fg
유니콘뉴스는 보도자료 배포 서비스입니다.
여기에 뉴스를 등록하면 언론이 보도하고 널리 배포됩니다.